Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.
Adductor laryngeal breathing dystonia (ALBD) is a rare disorder in which patients have persistent inspiratory stridor, usually normal voice, and cough. Physical exam is characterized by paradoxical movement of the vocal cords on inspiration. These patients have involuntary action-induced spasms of the adductor laryngeal muscles on inspiration. There has been no uniformly satisfactory treatment for the disease. Speech therapy, psychotherapy, and pharmacotherapy have all had limited success. We report the successful use of botulinum toxin type A in seven patients with adductor laryngeal breathing dystonia. All patients received bilateral thyroarytenoid injections. All patients had toxin effect within 72 hours, reaching maximal effect within 2 weeks with sustained improvement for an average of 13.8 weeks. Adverse effects included breathy voice and mild choking on liquids. Both resolved, on average, within 2 weeks. This retrospective study supports the safe and effective use of botulinum toxin type A in the treatment of adductor laryngeal breathing dystonia.
Grillone
G A
GA
Department of Otolaryngology, Boston University Medical Center, MA.
Blitzer
A
A
Brin
M F
MF
Annino
D J
DJ
Saint-Hilaire
M H
MH
D001905:Botulinum Toxins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007821:Laryngeal Muscles / Q000503:physiopathology*; D007826:Laryngismus / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012119:Respiration / Q000502:physiology*; D012135:Respiratory Sounds / Q000187:drug effects; D012189:Retrospective Studies; D013997:Time Factors; D014827:Vocal Cords / Q000503:physiopathology*; D014832:Voice Disorders / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*
D001905:Botulinum Toxins